Status:
COMPLETED
Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants
Lead Sponsor:
Novartis Vaccines
Conditions:
Haemophilus Influenzae Type b (Hib) Infection
Eligibility:
All Genders
365-569 years
Phase:
PHASE3
Brief Summary
This study will evaluate the safety and immunogenicity of booster dose of two commercially available vaccines used to prevent Haemophilus influenzae type b infections in children 365-569 days of age
Eligibility Criteria
Inclusion
- Infants 365-569 days of age.
Exclusion
- Subjects who already received a booster dose of Hib vaccine.
- History of serious reaction(s) following vaccination.
- Any vaccination within 7 days of study vaccination.
- Known or suspected immune impairment.
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
660 Patients enrolled
Trial Details
Trial ID
NCT01226953
Start Date
October 1 2010
End Date
March 1 2011
Last Update
December 30 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hebei Province, China